文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

靶向二代测序诊断耐药结核病的系统评价与荟萃分析

Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis.
PubMed 文献 · Lancet Infect Dis · 2024-05-22

该系统评价与荟萃分析检索了2005年1月1日至2022年10月14日多个数据库的靶向二代测序诊断耐药结核病报告,最终纳入24项诊断准确性研究进行荟萃分析。合并敏感度为94.1%(95%可信区间90.9-96.3),特异度为98.1%(97.0-98.9);部分现行推荐药物的数据匮乏,高负担国家应用障碍有待解决。

要点

  • 靶向二代测序检测结核分枝杆菌耐药性的合并敏感度为94.1%,特异度为98.1%。
  • 利福平敏感度99.1%,卡那霉素敏感度76.5%,乙胺丁醇特异度93.1%,阿米卡星特异度99.4%。
  • 直接检测临床样本与培养分离株的诊断准确性总体相似。

核心结论

  • 靶向二代测序对结核分枝杆菌耐药性检测具有高敏感度和高特异度,可直接在临床样本上进行。
  • 部分现行推荐药物的检测性能数据匮乏,需解决高负担国家应用靶向二代测序诊断耐药结核病的障碍。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、Embase、Cochrane图书馆、Web of Science核心合集、Global Index Medicus、Google Scholar、ClinicalTrials.gov及WHO国际临床试验注册平台,时间2005年1月1日至2022年10月14日,Embase和Google Scholar更新至2024年2月13日。
  • 系统评价纳入124篇报告,包括37篇综述和87篇收集样本进行靶向二代测序的研究报告;测序主要在美国(14/87,16%)、西欧(10/87,11%)、印度(10/87,11%)和中国(9/87,10%)进行。
  • 荟萃分析纳入24项诊断准确性研究,评估23种结核药物或药物组,主要比较靶向二代测序与表型药物敏感性试验,使用QUADAS-2工具评估偏倚风险,采用贝叶斯双变量模型。

主要发现

  • 靶向二代测序跨所有药物的合并敏感度为94.1%(95%可信区间90.9-96.3),合并特异度为98.1%(97.0-98.9)。
  • 单个药物敏感度从卡那霉素的76.5%(52.5-92.3)到利福平的99.1%(98.3-99.7);特异度从乙胺丁醇的93.1%(88.0-96.3)到阿米卡星的99.4%(98.3-99.8)。
  • 直接临床样本与培养分离株的诊断准确性总体相似,利福平、异烟肼、乙胺丁醇、链霉素和氟喹诺酮类亦然;排除高偏倚风险研究后总体敏感度95.2%(91.7-97.1)、特异度98.6%(97.4-99.3)。

局限性

  • 部分现行推荐药物的检测性能数据匮乏。
  • 需解决高负担国家应用靶向二代测序诊断耐药结核病的障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Targeted next-generation sequencing (NGS) can rapidly and simultaneously detect mutations associated with resistance to tuberculosis drugs across multiple gene targets. The use of targeted NGS to diagnose drug-resistant tuberculosis, as described in publicly available data, has not been comprehensively reviewed. We aimed to identify targeted NGS assays that diagnose drug-resistant tuberculosis, determine how widely this technology has been used, and assess the diagnostic accuracy of these assays. METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, Cochrane Library, Web of Science Core Collection, Global Index Medicus, Google Scholar, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform for published and unpublished reports on targeted NGS for drug-resistant tuberculosis from Jan 1, 2005, to Oct 14, 2022, with updates to our search in Embase and Google Scholar until Feb 13, 2024. Studies eligible for the systematic review described targeted NGS approaches to predict drug resistance in Mycobacterium tuberculosis infections using primary samples, reference strain collections, or cultured isolates from individuals with presumed or confirmed tuberculosis. Our search had no limitations on study type or language, although only reports in English, German, and French were screened for eligibility. For the meta-analysis, we included test accuracy studies that used any reference standard, and we assessed risk of bias using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. The primary outcomes for the meta-analysis were sensitivity and specificity of targeted NGS to diagnose drug-resistant tuberculosis compared to phenotypic and genotypic drug susceptibility testing. We used a Bayesian bivariate model to generate summary receiver operating characteristic plots and diagnostic accuracy measures, overall and stratified by drug and sample type. This study is registered with PROSPERO, CRD42022368707. FINDINGS: We identified and screened 2920 reports, of which 124 were eligible for our systematic review, including 37 review articles and 87 reports of studies collecting samples for targeted NGS. Sequencing was mainly done in the USA (14 [16%] of 87), western Europe (ten [11%]), India (ten [11%]), and China (nine [10%]). We included 24 test accuracy studies in the meta-analysis, in which 23 different tuberculosis drugs or drug groups were assessed, covering first-line drugs, injectable drugs, and fluoroquinolones and predominantly comparing targeted NGS with phenotypic drug susceptibility testing. The combined sensitivity of targeted NGS across all drugs was 94·1% (95% credible interval [CrI] 90·9-96·3) and specificity was 98·1% (97·0-98·9). Sensitivity for individual drugs ranged from 76·5% (52·5-92·3) for capreomycin to 99·1% (98·3-99·7) for rifampicin; specificity ranged from 93·1% (88·0-96·3) for ethambutol to 99·4% (98·3-99·8) for amikacin. Diagnostic accuracy was similar for primary clinical samples and culture isolates overall and for rifampicin, isoniazid, ethambutol, streptomycin, and fluoroquinolones, and similar after excluding studies at high risk of bias (overall sensitivity 95·2% [95% CrI 91·7-97·1] and specificity 98·6% [97·4-99·3]). INTERPRETATION: Targeted NGS is highly sensitive and specific for detecting drug resistance across panels of tuberculosis drugs and can be performed directly on clinical samples. There is a paucity of data on performance for some currently recommended drugs. The barriers preventing the use of targeted NGS to diagnose drug-resistant tuberculosis in high-burden countries need to be addressed. FUNDING: National Institutes of Allergy and Infectious Diseases and Swiss National Science Foundation.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Schwab TC, Perrig L, Göller PC, et al. Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2024. PMID: 38795712. doi:10.1016/S1473-3099(24)00263-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。